New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease Oct 22, 2014 02:30AM

CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, Oct. 22, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company") announces that Dr. Tomer Adar, a gastro-enterologist at the Institute for Digestive Diseases at Shaare Zedek Medical Center, Israel, is presenting today at the United European Gastro-Enterology week in Vienna, Austria an abstract entitled "The importance of intestinal eotaxin-1 - Eosinophil axis in inflammatory bowel disease, Results of a prospective observational study." The study was supported in part by an unrestricted grant from Immune.

Professor Eran Goldin, Chairman of the Institute for Digestive Diseases at Shaare Zedek Medical Center, part of the Hebrew University School of Medicine in Jerusalem, Israel, commented: "This prospective clinical observational study demonstrates the pivotal role of eotaxin-1 in both Ulcerative Colitis and Crohn's Disease. Ongoing and future clinical trials will assess the relevance of selecting patients based on high eotaxin-1 tissue levels to optimize treatment response with anti-eotaxin 1 drugs such as Bertilimumab."

According to the abstract presented by Professor Goldin's group, this observational clinical study demonstrates elevated tissue Eotaxin-1 levels in both Ulcerative Colitis and Crohn's Disease, especially in more severe, active disease. The increase in tissue but not in serum eotaxin-1 levels suggests its importance as a local mediator of mucosal inflammation. The correlation between tissue eotaxin-1 and tissue eosinophilia in active disease, marks its central role in mediating local inflammation. and also suggests that its role in the pathogenesis of Crohn's Disease is not restricted to eosinophil recruitment.

A previous study, supported in part by a National Institute of Health grant and published on December, 18, 2013 in PlosOne by Professor Keith Wilson at Vanderbilt University Medical Center, highlighted eotaxin-1 as an etiologic factor and therapeutic target in Ulcerative Colitis.

Coburn LA, Horst SN, Chaturvedi R, Brown CT, Allaman MM, et al. (2013) High-Throughput Multi-Analyte Luminex Profiling Implicates Eotaxin-1 in Ulcerative Colitis. PLoS ONE 8(12): e82300. doi:10.1371/journal.pone.0082300

About Ulcerative Colitis

Ulcerative colitis is a chronic, inflammatory immune-related disorder limited to the large bowel (colon and rectum) and only affects the inner lining of the colon. The main symptom is diarrhea that is generally bloody and may be associated with abdominal pain. Loss of appetite and subsequent weight loss are common, as is fatigue. Severe bleeding may result in anemia. Ulcerative colitis can be debilitating and sometimes can lead to life-threatening complications. The symptoms of ulcerative colitis tend to come and go, with fairly long periods in between flare-ups in which patients may experience no distress at all. Major surgery is often involved, and can cure the disease.

About Crohn's Disease

Crohn's disease is an immune-related, chronic inflammatory condition (auto-immune) that can involve any part of the gastrointestinal tract, but most frequently affects the end of the small bowel and the beginning of the large bowel. In Crohn's disease, all layers of the intestine may be involved and there can be normal healthy bowel between patches of diseased bowel. Symptoms include persistent diarrhea, abdominal pain, fever, and occasionally, rectal bleeding. Fatigue, loss of appetite and weight loss also may occur. There is no cure for the disease.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.  The Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe Ulcerative Colitis as well as Bullous Pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca.  Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and Amiket™, a Neuropathic Pain drug candidate ready for Phase III. Amiket has received Orphan Drug Designation for Post Herpetic Neuralgia.

For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.

Erik Penser Bankaktiebolag is engaged as Immune's Certified Adviser on NASDAQ OMX First North Premier.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking.  Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet™ will not be successful; the risk that bertilimumab, AmiKet™ or compounds arising from our NanomAb® program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-clinical-data-supports-development-of-bertilimumab-in-both-ulcerative-colitis-and-crohns-disease-405025186.html

SOURCE Immune Pharmaceuticals Inc.


Millicom International Cellular: Millicom to drive data takeup with smartapps Oct 22, 2014 02:17AM

- premium apps bundled in monthly packages

- popular apps include Tigo Music, Qello and Gameloft

- new campaign to drive digital lifestyle adoption

STOCKHOLM--(BUSINESS WIRE)-- Millicom (Stockholmsbörsen: MIC), the international telecommunications and media company, announced today the launch of its Tigo “smartapps” service to drive further takeup of data and smartphone usage in Latin America.

The smartapps service: bundling premium services with data

Tigo’s post-paid customers will be able to choose and activate from a group of premium applications included in their monthly data plan:

- Tigo Music: featuring 30 million streamed tracks as well as an online listening facility

- Qello: exclusive full-length HD music documentaries and concerts spanning all genres

- Gameloft: users select four games each month such as Sonic, Assassin’s Creed and Spiderman

- Busuu: with over 200 hours of online lessons to learn eleven different languages, including English, German, French and more.

- Smartbooks: Tigo’s own smartbooks app has a library of 1,000 titles.

With APPtualizate, Tigo’s prepay customers will be able to discover from dozens of apps, which will include locally-relevant content such as maps, cooking, fitness, basic music and film.

The service begins its full rollout in Colombia and will be available in El Salvador and Bolivia later this month and in all Latin American Tigo markets by the end of the first quarter of 2015. With low penetration of debit and credit cards in these countries, the service is a simple way for customers to access mobile content.

Over the past year Millicom has experienced a significant rise in the number of its customers taking data packages with one in four now having mobile online access. Its drivers have included Tigo Music with over 600,000 customers and the FIFA World Cup app which was a top download in five Tigo markets. This has been boosted by the wide availability of smartphones at around $45.

The smartapps campaign: guiding and motivating the consumer

The first phase of the smartapps marketing campaign in Colombia, including a TV spot filmed in Medellin, features the simplicity of using apps on mobile devices as well as the extraordinary range of content available.

It shows the millions of consumers who may be unfamiliar with the concept of apps, how they work and how useful and entertaining they can be to position Tigo as a trusted and friendly provider.

The campaign reinforces the Tigo Smart brand which promotes a selection of smartphone products and services designed to make customers’ lives easier and the smartphone experience more fun.

Commenting on the launch of the new service today, Millicom’s CEO and President Hans-Holger Albrecht said “Online use on the go keeps on growing and now our smartapps service will reinforce this decisive shift from voice to data use on mobile devices. It’s a key part of our strategy to provide a digital lifestyle and promote stronger customer loyalty with valued services and attractive bundles.”

About Millicom

Millicom (STO: MIC) is a leading international telecommunications and media company dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing digital lifestyle services to the world’s emerging markets, giving access to the world, primarily through mobile devices. Operating in fourteen countries, primarily using the Tigo brand, Millicom offers innovative and customer-centric products. Millicom employs more than 16,000 people and provides mobile, cable, broadband, TV content, online and financial services to over 50 million customers. Founded in 1990, Millicom is headquartered in Luxembourg and listed on NASDAQ OMX Stockholm under the symbol MIC. In 2013 Millicom generated revenue of $5.16 billion and EBITDA of $1.9 billion.

This information was brought to you by Cision http://news.cision.com

Millicom International Cellular

For more please visit: www.millicom.com or contact:

Press Enquiries:

Julian Eccles, VP, Corporate Communications

+44 7720 409374

press@millicom.com

or

Investor Enquiries:

Nicolas Didio, Director of Investor Relations

+44 203 249 2220

investors@millicom.com

Source: Millicom International Cellular


Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2014 Oct 22, 2014 02:15AM

KYOTO, Japan, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Nidec Corporation (NYSE: NJ) today announced its consolidated results under U.S.GAAP for the period of April 1, 2014 through September 30, 2014.

The highlights are as follows:

  • Record-high first half-year net sales of 489.5 billion yen
  • Operating income up 34% Y/Y to 52.7 billion yen, marking six consecutive quarters of increase with the V-shaped recovery momentum sustained since the structural reform in FY2012
  • Record-high first half-year income before income taxes and net income
  • Diluted EPS: 126.53 yen (for the six months ended September 30, 2014)
  • Interim dividend: 30 yen per share
  • Projected annual dividend: 60 yen per share

Selected Consolidated Results of Operations (Unaudited)

         
Yen in millions, except for per share amounts and percentages Six months ended September 30, Increase (Decrease) Three months ended  September 30, Increase (Decrease)
       %      %
  2014 2013   2014 2013  
Net sales  489,511 429,634 13.9% 249,323 218,358 14.2%
Operating income  52,676 39,337 33.9% 27,124 21,290 27.4%
Ratio of operating income to net sales  10.8% 9.2%  -- 10.9% 9.8%  --
Income before income taxes  52,291 38,441 36.0% 27,320 21,075 29.6%
Ratio of income before income taxes to net sales  10.7% 8.9% -- 11.0% 9.7%  --
Net income attributable to Nidec Corporation  37,209 27,103 37.3% 19,292 13,757 40.2%
Ratio of net income attributable to Nidec Corporation to net sales 7.6% 6.3% -- 7.7% 6.3%  --
Net income attributable to Nidec Corporation per share-basic*  134.91 100.99 -- 69.95 51.26  --
Net income attributable to Nidec Corporation per share-diluted*  126.53 94.27  -- 65.61 47.85  --
*We implemented a two-for-one stock split of our common stock effective April 1, 2014. The previously reported net income attributable to Nidec Corporation per share-basic and net income attributable to Nidec Corporation per share-diluted have been retroactively adjusted to reflect the stock split.

Full copy of Nidec's financial statements for the second quarter and six months ended September 30, 2014: http://www.nidec.com/en-Global/ir/news/2014/news1022-01/

A conference call webcast (audio-only, user-control slides attached) discussing Nidec's financial results for the second quarter ended September 30, 2014 is scheduled for 09:00 a.m. EDT on Thursday, October 23, 2014. To listen to the webcast, please visit Nidec website at: http://www.nidec.com/en-Global/ir/calendar/schedule/archive/FY14Q2/

About Nidec Corporation

Nidec Corporation (NYSE: NJ) (Tokyo:6594) is a global leader in electric motor drive technology. For the six months ended September 30, 2014, 38.9% of its consolidated sales were represented by small precision motors; 25.6% by appliance, commercial and industrial products; 19.0% by automotive products; 9.2% by machinery; 6.6% by electronic and optical components, and 0.7% by the remaining product lines. Nidec was founded in Kyoto, Japan in 1973 by Shigenobu Nagamori, its current President and CEO.

CONTACT: Masahiro Nagayasu
         General Manager
         Investor Relations
         +81-75-935-6140
         ir@nidec.com

Source: Nidec Corporation


Nidec Announces Financial Results for Fiscal Second Quarter and Six Months Ended September 30, 2014 Oct 22, 2014 02:15AM

KYOTO, Japan, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Nidec Corporation (NYSE: NJ) today announced its consolidated results under U.S.GAAP for the period of April 1, 2014 through September 30, 2014.

The highlights are as follows:

  • Record-high first half-year net sales of 489.5 billion yen
  • Operating income up 34% Y/Y to 52.7 billion yen, marking six consecutive quarters of increase with the V-shaped recovery momentum sustained since the structural reform in FY2012
  • Record-high first half-year income before income taxes and net income
  • Diluted EPS: 126.53 yen (for the six months ended September 30, 2014)
  • Interim dividend: 30 yen per share
  • Projected annual dividend: 60 yen per share

Selected Consolidated Results of Operations (Unaudited)

         
Yen in millions, except for per share amounts and percentages Six months ended September 30, Increase (Decrease) Three months ended  September 30, Increase (Decrease)
       %      %
  2014 2013   2014 2013  
Net sales  489,511 429,634 13.9% 249,323 218,358 14.2%
Operating income  52,676 39,337 33.9% 27,124 21,290 27.4%
Ratio of operating income to net sales  10.8% 9.2%  -- 10.9% 9.8%  --
Income before income taxes  52,291 38,441 36.0% 27,320 21,075 29.6%
Ratio of income before income taxes to net sales  10.7% 8.9% -- 11.0% 9.7%  --
Net income attributable to Nidec Corporation  37,209 27,103 37.3% 19,292 13,757 40.2%
Ratio of net income attributable to Nidec Corporation to net sales 7.6% 6.3% -- 7.7% 6.3%  --
Net income attributable to Nidec Corporation per share-basic*  134.91 100.99 -- 69.95 51.26  --
Net income attributable to Nidec Corporation per share-diluted*  126.53 94.27  -- 65.61 47.85  --
*We implemented a two-for-one stock split of our common stock effective April 1, 2014. The previously reported net income attributable to Nidec Corporation per share-basic and net income attributable to Nidec Corporation per share-diluted have been retroactively adjusted to reflect the stock split.

Full copy of Nidec's financial statements for the second quarter and six months ended September 30, 2014: http://www.nidec.com/en-Global/ir/news/2014/news1022-01/

A conference call webcast (audio-only, user-control slides attached) discussing Nidec's financial results for the second quarter ended September 30, 2014 is scheduled for 09:00 a.m. EDT on Thursday, October 23, 2014. To listen to the webcast, please visit Nidec website at: http://www.nidec.com/en-Global/ir/calendar/schedule/archive/FY14Q2/

About Nidec Corporation

Nidec Corporation (NYSE: NJ) (Tokyo:6594) is a global leader in electric motor drive technology. For the six months ended September 30, 2014, 38.9% of its consolidated sales were represented by small precision motors; 25.6% by appliance, commercial and industrial products; 19.0% by automotive products; 9.2% by machinery; 6.6% by electronic and optical components, and 0.7% by the remaining product lines. Nidec was founded in Kyoto, Japan in 1973 by Shigenobu Nagamori, its current President and CEO.

CONTACT: Masahiro Nagayasu
         General Manager
         Investor Relations
         +81-75-935-6140
         ir@nidec.com

Source: Nidec Corporation


Millicom International Cellular: Transformation and growth as UNE makes a strong start Oct 22, 2014 02:13AM

LEUDELANGE, Sweden--(BUSINESS WIRE)-- Key highlights of Q3 2014

· Organic revenue growth(a) of 8.6%.

· Strong momentum in Colombia;

o Mobile service revenue growth of 20.5%.

o UNE makes a strong contribution with $52 million EBITDA (27.8% EBITDA margin).

· 1.46 million mobile net adds, mostly driven by Tanzania, DRC and Colombia.

· DTH encouraging take-up - customer base now close to 45,000.

· 103,000 new homes passed – footprint in cable now exceeds 5.4 million homes passed(b).

· Q3 EBITDA(c) at $549 million - margin at 32.8%; o Excluding UNE, EBITDA of $497 million and 33.4% margin.

Key financial indicators(d)

$m   Q3 2014(e)   Q3 2013(f)   % change   9M 2014   9M 2013   % change
 
Revenue 1,674 1,383 21.00% 4,527 4,089 10.80%
Organic revenue growth(a) 8.60% 6.10% 2.5ppt 8.70% 4.60% 4.1ppt
Of which UNE 186 N/A 186 N/A
EBITDA(c) 549 487 12.70% 1,506 1,499 0.50%
Of which UNE 52 N/A 52 N/A
EBITDA margin 32.8% 35.20% (2.4ppt) 33.30% 36.70% (3.4ppt)
EBITDA margin excl. UNE 33.40% 35.20% (1.8ppt) 33.50% 36.70% (3.2ppt)
Capex / sales ratio(g) 19.80% 21.70% (1.9ppt) 16.80% 15.00% 1.8ppt
Capex / sales excl. UNE 19.30% 21.70% (2.4ppt) 17.00% 15.00% 2.0ppt
Equity FCF 131 76 72.40% -57 -52 -9.60%
Adjusted EPS ($) (h) 0.79 0.72 9.70% 1.41 2.57 (45.1%)

· Mobile: Mobile revenue grew by 7.6% reflecting strong handset sales. Service revenue grew by 4.7% driven by mobile data, which accelerated to +34.7% (+32.4% in Q2), offsetting the decline of voice & SMS (-1.4%).

· Cable & Digital Media: the demand for our products remains strong. The ratio RGUs / households keeps increasing (+3.8% to 1.43x ex UNE) and 2Play/3Play customer base continues to grow (+20.0% year-on-year).

· Mobile Financial Services (MFS): 564,000 new customers with strong take-up in Tanzania and El Salvador. Revenue grew by 44.6% with the ARPU growing 12.0% sequentially (6.8% decline compared to Q3 2013).

· Cost & Capex Optimisation:efficiency and optimization programme started in Guatemala have been extended to 3 other countries (Bolivia, Tanzania, El Salvador). In Africa, our new Managed Services contract will boost the network quality while delivering cost savings.

a Organic growth represents year-on year-growth in local currency (excludes the impact of exchange rate changes) – it excludes UNE in Q3

b Including UNE

c EBITDA: derived from deducting cost of sales, sales & marketing costs, general & administrative expenses (including corporate costs) from revenue and adding other operating income

d Q3 2014 & 9M 2014 include UNE from 14th August. Q3 2013 and 9M 2013 do not include UNE

e Millicom owns 50% minus one share of UNE but consolidates 100% of UNE

f Proforma to reflect full consolidation of Guatemala, and equity accounting for Mauritius and Online

g Capex excluding spectrum and licence acquisitions

h Basic EPS adjusted for non-operating items see page 15 for reconciliation

President’s Statement

Transformation and growth as UNE makes a strong start

Stockholm, 22 October 2014

“It has been a momentous quarter with the completion of the merger with UNE in August. Our partnership with UNE has made a very solid contribution recording revenue slightly ahead of our own expectation and EBITDA at a 28% margin. It is very early days and the team are focussed on the considerable task of integration but together with the Tigo mobile business, which maintained its momentum in Q3, we see an exciting future opportunity.

Across the Tigo business we continued to see the benefits of the work we have undertaken over the last two years, which we highlighted at our Capital Markets Day in Miami at the end of last month. Organic revenue growth at 8.6%, excluding UNE, was a good achievement. Revenue maintained momentum not just in Colombia, but also in Bolivia, Guatemala and across the African businesses which achieved 12% organic service revenue growth in the quarter. It keeps us firmly on track for our $9bn revenue target in 2017.

We also had a good quarter in the Cable & Digital Media business. Tigo Star has extended its services with five of seven markets in Latin America now offering satellite payTV - making it available to tens of millions of people in rural areas and complementing our cable services. At the end of September, we had 45,000 customers on this service and our monthly take-up rate is accelerating. This is an impressive adoption rate and is very encouraging for the future development of this product.

We are continuing the transformation of the company elsewhere with the promotion and take-up of mobile data services with Smartapps in Latin America and Tigo Music in Africa both launching this month. Data users have risen 13% over the last three months and now comprise 25% of our mobile customer base.

Innovation in mobile money has gathered pace with the launch this quarter in Tanzania of the world’s first service offering a direct return on balances as well as the start of Africa’s first interoperable MFS. Overall, MFS has grown organically by 45%.

We have intensified action on efficiencies right across the company. We continue the rigorous country-by-country, function-by-function programme which has already identified important savings in one of our key markets.

At our recent Capital Markets Day, we affirmed our target of long term EBITDA margin of around 35% but, more importantly, operating cash flow margin of 20%. The success of our business in driving forward profitable revenue growth will be a key factor in achieving these goals and the results so far give me confidence in our capacity to deliver.”

Hans-Holger Albrecht President and CEO, Millicom

2014 Guidance

Target Guidance (excluding UNE) YTD Revenue (i) We expect revenue growth(a) to accelerate at a mid to high 8.7% single digit rate (versus comparable 5.5% in 2013) (ii) Reported revenue growth at constant exchange rate vs. 19.7% 2013 over 15% EBITDA EBITDA margin will stabilize around the mid-30s% mark 33.5% Capex In 2014, we expect a capex to revenue ratio of around 19%, 17.0% excluding spectrum and license acquisitions

Shareholder remuneration

We reiterate our dividend policy for no less than $2 per share and at least 30% of normalised net income.

We continue to have the ambition to progressively grow ordinary dividends. However our immediate priority will be on reducing Group leverage towards the middle of our target range of 1.0-2.0x Net Debt/EBITDA.

Nomination Committee for the 2015 Annual General Meeting

In accordance with the resolution of the 2014 Annual General Meeting, Cristina Stenbeck has convened a Nomination Committee consisting of members representing the largest shareholders in Millicom. The Nomination Committee is comprised of Cristina Stenbeck, Investment AB Kinnevik, Mathias Leijon, Nordea Funds and Tomas Risbecker, AMF and AMF Funds. The members of the Committee will appoint the Committee Chairman at their first meeting.

Shareholders wishing to propose candidates for election to the Board of Directors of Millicom should submit their proposal in writing to the Company Secretary, Millicom International Cellular SA, 2 rue du Fort Bourbon, BP 2312 L-1023 Luxembourg, Luxembourg.

Conference call details

A presentation and conference call to discuss results of the quarter will take place at 14.00 Stockholm / 14.00 Luxembourg / 13.00 London / 08.00 New York, on Wednesday 22 October, 2014. Dial-in numbers: + 46 (0) 850 51 3793, + 352 2088 0359, + 44 (0) 207 784 1036, + 1 646 254 3365. Access code: 3783379

A live audio stream of the conference call can also be accessed at www.millicom.com. Please dial in / log on 10 minutes prior to the start of the conference call to allow time for registration.

Slides to accompany the conference call are available at www.millicom.com.

a Under 2014 consolidation scope at constant exchange rates

Significant events of the quarter

Corporate news

16th July 2014: Millicom reaches agreement to sell its 50% stake in EMTEL (Mauritius)

3rd Aug 2014: Millicom merger with UNE receives third regulatory approval

14th Aug 2014: Completion of the merger with UNE in Colombia

Business news

09th July 2014: Millicom launches mobile education EduMe in Africa and Latin America

24th July 2014: 4G launches in Bolivia

13th Aug 2014: Exclusive music in Latin America: Tigo Sessions with multi Grammy award winner Juanes

10th Sept 2014: Millicom launches the world’s first mobile money service with automatic returns to users

11th Sept 2014: Millicom and Kalixa create online payments processing partnership for Africa and Latin America

24th Sept 2014: Millicom debuts digital music initiatives for Africa

Financial news

16th July 2014: Publication of Q2 results

24th Sept 2014: Capital Markets Day in Miami: Millicom confirms ambitious $9bn revenue target

Subsequent events

There were no subsequent events between 30 September and 22 October.

Agenda

3rd February 2015: FY 2014 results

22nd April 2015: Q1 15 results

Millicom is a leading telecom and media company dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing innovative and customer-centric digital lifestyle services to the world’s emerging markets, giving access to the world, primarily through mobile devices. The Millicom Group employs more than 16,000 people and provides mobile services to over 53 million customers. Founded in 1990, Millicom International Cellular SA is headquartered in Luxembourg and listed on NASDAQ OMX Stockholm under the symbol MIC. In 2013, Millicom generated revenue of USD 5.16 billion and EBITDA of USD 1.88 billion.

This press release may contain certain “forward-looking statements” with respect to Millicom’s expectations and plans, strategy, management’s objectives, future performance, costs, revenue, earnings and other trend information. It is important to note that Millicom’s actual results in the future could differ materially from those anticipated in forward-looking statements depending on various important factors.

All forward-looking statements in this press release are based on information available to Millicom on the date hereof. All written or oral forward-looking statements attributable to Millicom International Cellular S.A., and Millicom International Cellular S.A. employees or representatives acting on Millicom’s behalf are expressly qualified in their entirety by the factors referred to above. Millicom does not intend to update these forward-looking statements.

This information was brought to you by Cision http://news.cision.com

Millicom International Cellular:

Press

Julian Eccles, VP, Corporate Communications

Tel: +352 277 59084 (Luxembourg)

+44 7720 409 374

press@millicom.com

or

Investor Relations

Nicolas Didio, Director, Head of Investor Relations

Tel: +352 277 59125 (Luxembourg)

+44 203 249 2220

investors@millicom.com

Source: Millicom International Cellular


More Press Releases

View Older Stories

Oct 22, 2014 02:05AM Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
Oct 22, 2014 02:05AM APS Upset Training President Joins NBAA Safety Committee
Oct 22, 2014 02:02AM Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
Oct 22, 2014 02:01AM BARC's The BI Survey 14: "Cloud Business Intelligence is clearly a space Yellowfin dominates"
Oct 22, 2014 02:01AM JASON RUEDY: The Home Loan Arranger, Urges Potential Buyers to Investigate Vacation Home Buying Opportunities
Oct 22, 2014 02:01AM Asplundh Adds Propane Autogas Trucks to its Fleet
Oct 22, 2014 02:00AM Tricks, Treats, Ghosts, Goblins Abound in New Halloween Story
Oct 22, 2014 02:00AM How the Entitlement Mentality is Hurting Marriages, Explains Relationship Expert Hellen Chen
Oct 22, 2014 02:00AM Avid Collector Seeks Vintage Jimi Hendrix 1969 Sportpalast Berlin Germany Concert Poster
Oct 22, 2014 02:00AM Memoir reveals Hollywood's lights, shadows in poetry
Oct 22, 2014 02:00AM DSP Group Delivers HD Voice and Home Automation Utilizing Qualcomm Internet Processor
Oct 22, 2014 02:00AM Key Properties at Runway Playa Vista Choose Allura for Protection
Oct 22, 2014 02:00AM DSP Group Delivers HD Voice and Home Automation Utilizing Qualcomm Internet Processor
Oct 22, 2014 02:00AM GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Designation From European Medicines Agency for the Treatment of Dravet Syndrome
Oct 22, 2014 02:00AM Eurotunnel Group: Activity in the Third Quarter of 2014
Oct 22, 2014 02:00AM B/E Aerospace Reports Third Quarter 2014 Financial Results
Oct 22, 2014 02:00AM Lewis Roca Rothgerber Welcomes Four New Associates in Phoenix
Oct 22, 2014 02:00AM Women Hold Greater Proportion of CEO and Board Seats at Non-Profits Than at For-Profit Companies in the Philadelphia Region
Oct 22, 2014 02:00AM BGC Partners Commences Cash Tender Offer To Acquire GFI Group For $5.25 Per Share
Oct 22, 2014 01:59AM Yingli Green Energy Hosts Fifth Annual Global Investor Day in Las Vegas, USA
Oct 22, 2014 01:55AM NoHo Urgent Care Offers Exclusive $85 Medical Exams for Patients
Oct 22, 2014 01:37AM DBV Technologies S.A. Announces Pricing of Global Offering
Oct 22, 2014 01:37AM DBV Technologies S.A. Announces Pricing of Global Offering
Oct 22, 2014 01:35AM Author Reveals Thoughts through Book of Personal Commentaries
Oct 22, 2014 01:20AM TECHNICOLOR : Third quarter 2014 Revenues
Oct 22, 2014 01:15AM New Biography Shows Exciting Life of Lone Ranger's Radio Show Actor
Oct 22, 2014 01:15AM Wholesale Stainless Steel Exit Buttons Provided by Chinese Magnetic Lock Supplier Locks-Magnetic.com
Oct 22, 2014 01:15AM ASETEK – Q3 2014 Progress in Both Segments
Oct 22, 2014 01:14AM The Best Cheap WordPress Hosting Companies In 2014 Revealed –Top10BestSEOHosting.com
Oct 22, 2014 01:05AM Daniel Pink, NYT Bestselling Author, Partners with RiseSmart to Host "Think Like A Leader: Drive Your HR Career" Webinar
Oct 22, 2014 01:03AM Norsk Hydro : Third quarter 2014: Lower Alunorte costs and higher all-in metal price lift results
Oct 22, 2014 01:02AM Recycled Aluminium Innovation Supports Circular Economy
Oct 22, 2014 01:02AM Young Teens Are Crowned UK's Best Young Drivers - Before Legal Driving Age
Oct 22, 2014 01:02AM M. Scott Robertson's Crime Thriller Receives New Marketing Push
Oct 22, 2014 01:01AM CCW Global Deploys Cyber Insurance Facilities to Assist With Digital Risk Cover
Oct 22, 2014 01:01AM The Culinary School at Eva's Village Provides Job Training But More Importantly Assists Students in Finding Positions in the Food Service Industry
Oct 22, 2014 01:01AM eMazzanti Offers Hands-on Microsoft Office 365 Experience to NYC Area Businesses
Oct 22, 2014 01:01AM Advisory - Thurs. Oct.23, 1:00 PM at Curtis Hixon Park: Two Henrys Brewing Company Honors Florida Railroad Barons Henry Plant and Henry Flagler
Oct 22, 2014 01:00AM Douglas County Schools Hyundai Raffle Raises Over $45,000
Oct 22, 2014 01:01AM Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
Oct 22, 2014 01:00AM Ocean Reef Vacation Rentals & Real Estate Is Official Sponsor of 2014 30A 10K Race
Oct 22, 2014 01:00AM Local Schools Can Earn Funds With Gold'n Plump® Purchases
Oct 22, 2014 01:00AM Mina Group CFO Named 'Revolutionary CFO of the Year' - 7th Annual MENA CFO Awards
Oct 22, 2014 01:00AM Switzerland is the Best Place for Expat Life
Oct 22, 2014 01:00AM Dalma Capital Management and Emirates Foundation Sign Donation Agreement
Oct 22, 2014 01:00AM Nova Medical to Open New Occupational Medicine Center in Arlington, Texas
Oct 22, 2014 01:00AM AssetOptics Announces the Release of AssetOptics 2.6
Oct 22, 2014 01:00AM Leading Indonesian Online Marketplace Tokopedia Secures $100 Million Investment from SoftBank Internet and Media and Sequoia Capital
Oct 22, 2014 01:00AM bioMérieux - Business Review for the Nine Months Ended September 30, 2014
Oct 22, 2014 01:00AM CAGW Praises Sen. Coburn’s Wastebook 2014
View Older Stories